• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Nasdaq Biotechnology Index Falls

    Morag Mcgreevey
    Sep. 28, 2015 10:35AM PST
    Biotech Investing

    U.S. stocks were down today, with biotechnology companies extending the previous week’s selloff.

    U.S. stocks were down today, with biotechnology companies extending the previous week’s selloff.
    According to Bloomberg:

    The Nasdaq Biotechnology Index sank 4.5 percent after its worst week since 2011. Freeport-McMoRan Inc. tumbled 12 percent as copper dropped to the lowest in a month amid evidence of industrial weakness in China. Halliburton Co. and Marathon Oil Corp. lost at least 4.7 percent as oil prices slid. Amazon.com Inc. and Facebook Inc. fell more than 3.8 percent as investors sold some of the year’s better performers. Alcoa Inc. rose 2.4 percent after saying it will split into two publicly traded companies.
    The Standard & Poor’s 500 Index fell 2 percent to 1,893.76 at 12:24 p.m. in New York, its lowest in a month. The Dow Jones Industrial Average lost 241.41 points, or 1.5 percent, to 16,073.26. The Nasdaq Composite Index dropped 2.2 percent.
    “We are in a chaotic market, lots of volatility but not making much progress in either direction,” said James Gaul, a portfolio manager at Boston Advisors LLC, which oversees $2.8 billion. “Earnings are going to be really important this quarter considering the macro backdrop and general global fears as well as the concerns about the Fed potentially raising interest rates as early as next month.”

    Click here to read the full article.

     

    biotechnology companieschinadow jones
    The Conversation (0)

    Go Deeper

    AI Powered
    Life Science Investing

    Markets Rise Again After Coronavirus Fears Spark Selloff

    iShares U.S. Pharmaceuticals ETF

    Latest News

    Seegnal Inc. Announces Extension of Maccabi Health Services Contract

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×